Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children’s Oncology Group
JNCI: Journal of the National Cancer Institute · 2023
DOI: 10.1093/jnci/djad055 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Bailey A Martin-Giacalone und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Cancer Prevention and Research Institute of Texas.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Relative to other pediatric cancers, survival for rhabdomyosarcoma (RMS) has not improved in recent decades, suggesting the need to enhance risk stratification. Therefore, we conducted a genome-wide association study for event-free survival (EFS) and overall survival (OS) to identify genetic variants associated with outcomes in individuals with RMS.
Methods
The study included 920 individuals with newly diagnosed RMS who were enrolled in Children’s Oncology Group protocols. To assess the association of each single nucleotide polymorphism (SNP) with EFS and OS, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) using multivariable Cox proportional hazards models, adjusted for clinical covariates. All statistical tests were two sided. We also performed stratified analyses by histological subtype (alveolar and embryonal RMS) and carried out sensitivity analyses of statistically significant SNPs by PAX3/7-FOXO1 fusion status and genetic ancestry group.
Results
We identified that rs17321084 was associated with worse EFS (HR = 2.01, 95% CI = 1.59 to 2.53, P = 5.39 × 10−9) and rs10094840 was associated with worse OS (HR = 1.84, 95% CI = 1.48 to 2.27, P = 2.13 × 10−8). Using publicly available data, we found that rs17321084 lies in a binding region for transcription factors GATA2 and GATA3, and rs10094840 is associated with SPAG1 and RNF19A expression. We also identified that CTNNA3 rs2135732 (HR = 3.75, 95% CI = 2.34 to 5.99, P = 3.54 × 10−8) and MED31 rs74504320 (HR = 3.21, 95% CI = 2.12 to 4.86, P = 3.60 × 10−8) were associated with worse OS among individuals with alveolar RMS.
Conclusions
We demonstrated that common germline variants are associated with EFS and OS among individuals with RMS. Additional replication and investigation of these SNP effects may further support their consideration in risk stratification protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
- Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
- Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
ORCID-Profile: Bailey A Martin-Giacalone, Donald A Barkauskas, David Hall, Aniko Sabo, Douglas S Hawkins, Philip J Lupo
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Cancer Prevention and Research Institute of Texas
- QuadW Foundation
- Children’s Oncology Group Foundation
- St. Baldrick’s Foundation
- Isabella Santos Foundation
- National Cancer Institute
Zitieren
APA
Martin-Giacalone, B. A., Richard, M. A., Scheurer, M. E., Khan, J., Sok, P., Shetty, P. B., Chanock, S. J., Li, S. A., Yeager, M., Marquez-Do, D. A., Barkauskas, D. A., Hall, D., McEvoy, M. T., Brown, A. L., Sabo, A., Scheet, P., Huff, C. D., Skapek, S. X., Hawkins, D. S., …, & Lupo, P. J. (2023). Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children’s Oncology Group. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad055
Vancouver
Martin-Giacalone BA, Richard MA, Scheurer ME, Khan J, Sok P, Shetty PB, et al. Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children’s Oncology Group. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djad055
BibTeX
@article{MartinGiacalone2023,
author = {Martin-Giacalone, Bailey A and Richard, Melissa A and Scheurer, Michael E and Khan, Javed and Sok, Pagna and Shetty, Priya B and Chanock, Stephen J and Li, Shengchao Alfred and Yeager, Meredith and Marquez-Do, Deborah A and Barkauskas, Donald A and Hall, David and McEvoy, Matthew T and Brown, Austin L and Sabo, Aniko and Scheet, Paul and Huff, Chad D and Skapek, Stephen X and Hawkins, Douglas S and Venkatramani, Rajkumar and Mirabello, Lisa and Lupo, Philip J},
title = {Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children’s Oncology Group},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2023},
doi = {10.1093/jnci/djad055}
}
EUVIMED